Sometimes, toxic side effects aren’t discovered until fairly late in the medication development process, when considerable amounts of time and money have already been invested in clinical trials. Even though the pharmaceutical sector uses preclinical data and predictive algorithms to weed out drugs that are likely to fail due to toxicity, many still slide through the cracks. Now, a group of experts from Weill Cornell Medical University in NEW YORK has devised a fresh drug display that capitalizes on the inclination of toxic compounds to alter the properties of the lipid bilayer that encases cells. They shall present their screening technique at the 59th annual conference of the Biophysical Culture, held Feb.The settlement may be the third-largest settlement in a securities fraud case against a bio-technology firm concerning a drug approval. The suit was maintained by Staro Asset Administration, LLC on behalf of a debt class consisting of holders of Sepracor’s convertible debt securities, and by Westmont Venture Companions, LLC on behalf of an equity class consisting of holders of Sepracor’s common share, call options and put options. The two classes had been represented by a group of attorneys from Berger & Montague, P.C. Of Philadelphia; and Wolf Haldenstein Adler Freeman & Herz, LLP, NY, led by Sherrie R. Savett of Berger & Montague and Daniel W. Krasner of Wolf Haldenstein. Berger & Montague shareholder Gary E. Cantor and associate Joshua C. Schumacher, and Wolf Haldenstein partner David L.